Aligos Therapeutics (ALGS) Total Non-Current Liabilities (2019 - 2024)

Aligos Therapeutics (ALGS) has reported Total Non-Current Liabilities for 6 consecutive years, with $26.7 million the latest figure, recorded in Q4 2024.

• For the quarter ending Q4 2024, Total Non-Current Liabilities fell 16.17% year-over-year to $26.7 million; the trailing twelve-month figure through Dec 2024 stood at $26.7 million (down 16.17% YoY), and the FY2024 full-year result was $26.7 million, down 16.17% from the prior year.
• Total Non-Current Liabilities steadied at $26.7 million in Q4 2024 per ALGS's latest filing, from $26.7 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $57.4 million in Q1 2022 and bottomed at $26.1 million in Q1 2024.
• Historically, Total Non-Current Liabilities has averaged $39.6 million across 5 years, with a median of $42.3 million in 2021.
• The sharpest annual moves came in 2020 and 2024: Total Non-Current Liabilities surged 55.46% in 2020, then decreased 16.17% in 2024.
• Over 5 years, Total Non-Current Liabilities stood at $44.9 million in 2020, then climbed by 12.52% to $50.5 million in 2021, then retreated by 16.99% to $41.9 million in 2022, then declined by 24.02% to $31.9 million in 2023, then fell by 16.17% to $26.7 million in 2024.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $26.7 million, $26.7 million, and $30.1 million for Q4 2024, Q3 2024, and Q2 2024 respectively.